-
The big coffee will show you how the latest ASCO-GU research in 2022 will leverage new options for advanced prostate cancer treatment strategies
Time of Update: 2022-05-02
The latest published results of the PROpel study also confirmed that olaparib combined with abiraterone compared with abiraterone monotherapy can help first-line patients with metastatic castration-resistant prostate cancer (mCRPC) achieve better survival benefits [3] .
-
Prostate cancer should be checked at age?
Time of Update: 2022-05-02
Considering the impact of prostate cancer screening on people's quality of life and length of life, and the condition of most prostate cancer patients The development is relatively slow, and the "Guidelines" recommend that for high-risk groups under the age of 75 and with a life expectancy of more than 10 years, the first screening test using serum prostate-specific antigen (PSA) test is performed every two years .
-
The sea of stars, set sail - the 2022 edition of the "CSCO Prostate Cancer Diagnosis and Treatment Guidelines" update officially launched!
Time of Update: 2022-05-02
*Only for medical professionals to read and refer to the 2022 edition of the "CSCO Prostate Cancer Diagnosis and Treatment Guidelines" update work officially kicked off! Let us look forward to the ne
-
After ASCO GU 2022: Interpretation and reflection on mCSPC real-world data
Time of Update: 2022-05-02
The results showed that first-line triple-combination intensive therapy significantly delayed disease progression compared with first-line chemotherapy + ADT, and first-line new endocrine + ADT still needs further data generation and analysis .
-
Cure Bladder Cancer!
Time of Update: 2022-05-02
HK) announced that vedicitumab for injection (Aidexi®) combined with toripalimab injection ( Tuoyi®) for the treatment of perioperative muscle-invasive bladder cancer (MIBC) for the new drug clinical research application, obtained the implied approval for the clinical trial of the Center for Drug Evaluation (CDE) of the State Drug Administration .
-
Secret legend, Dengxinjing Prostate Cancer Summit Forum was grandly held, took stock of progress in the field, and gathered the essence of big coffee
Time of Update: 2022-05-02
*For medical professionals to read and refer to the 2022 AstraZeneca Prostate Cancer Summit Highlights Review . On February 26, 2022, the AstraZeneca Prostate Cancer Summit Forum was grandly held
-
【ASCO GU 2022】Professor Guo Hongqian commented: PROpel mCRPC is a safe and controllable treatment option for the whole population in the first line
Time of Update: 2022-05-02
Bone Marrow Distribution and Accumulation Concentrations of Different PARP Inhibitors Safety Profile of Combination Therapy in the 02PROpel Study Overall and grade 3 or higher adverse event rates were similar between combination therapy versus monotherapy .
-
Sprinting for the first-line treatment of urothelial carcinoma, the survival benefit of PD-L1 monoclonal antibody continues to improve, Yimaimeng broke the news
Time of Update: 2022-05-02
S. Food and Drug Administration granted Padcev conventional approval and expanded indication for the treatment of adult patients with locally advanced or mUC who are ineligible for cisplatin-based chemotherapy and have previously received first or multiple lines of therapy .
-
Professor Huang Yi walks side by side: the development and prospect of prostate cancer treatment under MDT mode
Time of Update: 2022-05-02
It is difficult for a single specialist to grasp the comprehensive treatment progress of such complex diseases and achieve the ideal However, through the MDT model, experts from related disciplines are gathered together to formulate individualized treatment plans for individual patients, which can maximize the benefit of patients .
-
2022 ASCO GU Individualized + Strong Combination Leads a New Era of Second-Line Treatment for Advanced UC
Time of Update: 2022-05-02
Phase II TROPHY-U-01 study showed that SG monotherapy demonstrated good antitumor activity and manageable safety in patients with mUC, and the objective of SG in patients after platinum-containing chemotherapy and immune checkpoint inhibitor progression The response rate (ORR) was 27%, and the median overall survival (OS) was 11 months .
-
What is the effect of 2022 ASCO GU radiotherapy + immunotherapy for penile squamous cell carcinoma?
Time of Update: 2022-05-02
Background: Patients with advanced penile squamous cell carcinoma (aPeCa) have a high incidence and poor prognosis (2-year overall survival rate of 21%) due to local disease progression .
-
Clinical Essentials: Common Causes and Pharmacological Treatment of Lower Urinary Tract Symptoms in Men
Time of Update: 2022-05-02
Definition and symptoms Male LUTS refers to a group of symptoms related to the lower urinary tract, which may originate from the bladder, prostate, urethra, and/or adjacent pelvic organs, and may also originate from anatomical structures innervated by similar, psychological factors , Central nervous system lesions such as cerebrovascular sclerosis, Parkinson's disease, etc.
-
2022 ASCO GU Prostate Cancer: Two Novel AR Inhibitors Are Emerging, and the Future of mCRPC Treatment Can Be Expected
Time of Update: 2022-05-02
Methods: In a phase I study, patients with mCRPC who had progressed after ≥2 prior treatments (enzalutamide and/or abiraterone) received oral ARV-110 (QD or BID) (3+3 dose-escalation design).
-
One-click collection: the latest consensus on guidelines for urinary tumors/urological diseases in January and February
Time of Update: 2022-05-02
It provides detailed evidence-based recommendations on 15 key issues, aiming to standardize the practice of prostate cancer screening and early diagnosis and treatment, and improve the prevention and control of prostate cancer in China .
-
【2022 ASCO-GU】Keep improving│Research progress in precision treatment of prostate cancer
Time of Update: 2022-05-01
2. Abstract #267: Transcriptome identification of prostate cancer patients with active surveillance of apalutamide therapy [2] A report at the 2020 SUO Congress on limited-stage very low-risk, low-risk and Preliminary results from a phase II study evaluating efficacy in low- and intermediate-risk prostate cancer patients showed that a significant proportion (59%) of patients had a positive re-biopsy pathology result after 90 days of apalutamide treatment.
-
Overcome "Social Cancer"!
Time of Update: 2022-05-01
March 9, 2022 / eMedClub PR News / -- Urovant Sciences, a clinical-stage biopharmaceutical company focused on developing treatments to improve urinary conditions, announced today that its first gene therapy, URO, for the treatment of overactive bladder (OAB) Phase 2a trials of -902 yielded positive results .
-
【2022 ASCO-GU】 New exploration of endocrine therapy for mHSPC in the future
Time of Update: 2022-05-01
Since the survival benefit of traditional CAB regimen compared with ADT alone in the treatment of metastatic prostate cancer is extremely limited, after weighing the efficacy and safety, major international guidelines no longer recommend traditional CAB as a long-term treatment for metastasis For the treatment of sex hormone-sensitive prostate cancer (mHSPC), novel endocrine therapy (NHT) represented by apalutamide is recommended as the first-line regimen .
-
Summary of the article: diagnosis and treatment of adrenal cortical carcinoma
Time of Update: 2022-05-01
Drug therapy Adjuvant therapy with mitotane is based on three major prognostic factors: tumor stage, completeness of resection, and proliferation rate .
1. Treatment benefits Adjuvant mitotane therapy can improve the outcomes of patients with stage II-IV ACC after surgery .
-
A review of the article: ASCO GU three major tumor types heavy research progress
Time of Update: 2022-05-01
Recommended reading: 2022 ASCO GU | Individualization + powerful combination, leading a new era of advanced UC second-line treatment of prostate cancer The exploration of cancer biomarkers is discussed .
-
【2022 ASCO-GU】Going a step further│The era of PARPi combined with abiraterone for the first-line treatment of mCRPC is coming?
Time of Update: 2022-05-01
Baseline Characteristics of HRR BM+ Patients in the MAGNITUDE Study In the BRCA1/2+ subgroup and all HRR BM+ patients, NIRA+AAP significantly improved BICR-assessed rPFS compared with PBO+AAP, with separate risk of radiographic progression or death The reductions were 47% (16.
